Agentix (AGTX) Income from Continuing Operations (2013 - 2026)
Agentix's (AGTX) quarterly Income from Continuing Operations came in at 77110.0 in Q1 2026, up 57.58% YoY from 48934.56 in Q1 2025, and up 1.89% on a QoQ basis from 78595.0 in Q4 2025.
Agentix (AGTX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Agentix (AGTX) has 14 years of Income from Continuing Operations data on file, last reported at 77110.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 57.58% year-over-year to 77110.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 485636.0 (up 14.36% YoY) and the FY2026 annual result came in at 485636.0, up 14.36% from the prior year.
- Income from Continuing Operations advanced to 77110.0 in Q1 2026, from 78595.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6374.0 in Q4 2023 to a low of 2017349.0 in Q1 2022.
- A 5-year average of 295823.06 and a median of 164654.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 101.8% — and 2025, when it sank 5962.98%.
- Tracing AGTX's Income from Continuing Operations over 5 years: stood at 353638.0 in 2022, then jumped by 101.8% to 6374.0 in 2023, then tumbled by 2357.51% to 143894.0 in 2024, then surged by 45.38% to 78595.0 in 2025, then climbed by 1.89% to 77110.0 in 2026.
- The last three Income from Continuing Operations figures came in at 77110.0 (Q1 2026), 78595.0 (Q4 2025), and 144107.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | -117,674.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117,674.00 |
| Mar 31, 2026 | -77,110.00 |
| Dec 31, 2025 | -78,595.00 |
| Sep 30, 2025 | -144,107.00 |
| Jun 30, 2025 | -185,824.00 |
| Mar 31, 2025 | -181,768.00 |
| Dec 31, 2024 | -143,894.00 |
| Sep 30, 2024 | -90,669.00 |
| Jun 30, 2024 | -150,717.00 |
| Mar 31, 2024 | -2,998.00 |
| Dec 31, 2023 | 6,374.00 |
| Sep 30, 2023 | -178,972.00 |
| Jun 30, 2023 | -409,558.00 |
| Mar 31, 2023 | -431,183.00 |
| Dec 31, 2022 | -353,638.00 |
| Sep 30, 2022 | -424,330.00 |
| Jun 30, 2022 | -164,654.00 |
| Feb 28, 2022 | -2.02 Mn |
| Nov 30, 2021 | -166,750.00 |
| Aug 31, 2021 | -243,426.00 |